Management of anaemia: A critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents

PharmacoEconomics

Volumn 26, Issue 2, 2008, Pages 99-120

  Duh, Mei Sheng ^a   Weiner, Jennifer R ^a   White, Leigh Ann ^a   Lefebvre, Patrick ^b   Greenberg, Paul E ^a  

^a ANALYSIS GROUP   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Anaemia, treatment; Cancer, contributory factors; Cost effectiveness; Cost utility; Darbepoetin alfa, therapeutic use; Epoetin alfa, therapeutic use; Epoetin beta, therapeutic use; Kidney disorders, contributory factors

Indexed keywords

ANTINEOPLASTIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CLINICAL DECISION MAKING; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DIALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG HALF LIFE; DRUG SAFETY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; NEOPLASM; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 38349054473     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826020-00002     Document Type: Review

References (75)

1. Duh MS, Latypova A, Greenberg P. Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives. Expert Rev Pharmacoeconomics Outcomes Res 2006 Oct; 6 (5): 577-90
2. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25: 43-6
3. Deray G. Achieving therapeutic targets in renal anaemia: considering cost-efficacy. Cur Med Res Opin 2004; 20 (7): 1095-101
4. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001; 91: 2214-21
5. Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006 Nov; 1 (6): 1205-10
6. Graber SE, Krantz SB. Erythropoietin: biology and clinical use. Hematol Oncol Clin North Am 1989 Sep; 3 (3): 369-400
7. Berenson A, Pollack A. Doctors reaping millions for use of anemia drugs. New York Times 2007 May 9; Sect A: 1
8. Thamer M, Zhang Y, Kaufman J, et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 2007 Apr 18; 297 (15): 1667-74
9. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998 Oct; 16; (10): 3412-25
10. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001 Jun 1; 19 (11): 2875-82
11. Boccia R, Lillie T, Tomita D, et al. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist 2007; 12: 584-93
12. Procrit® prescribing information [online]. Available from URL: http://www.procrit.com/procrit/shared/OBI/PI/ProcritBook-let.pdf#page=1 [Accessed 2007 May 1]
13. Epogen® prescribing information [online]. Available from URL: http://www.epogen.com/professional/resources/prescribing_information/pi.jsp [Accessed 2007 May 1]
14. NeoRecormon® prescribing information. European Medicines Agency (EMEA) [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/ EPAR/neorecormon/neorecormon.htm [Accessed 2007 Sep 4]
15. Macdougall IC, Gray S, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10 (11): 2392-5
16. Zamboni WC, Stewart CE. An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy 2002; 22 (9 Pt 2): 133S-40S
17. Aranesp® prescribing information [online]. Available from URL: http://www.aranesp.com/professional/prescribing_information.jsp [Accessed 2007 May 1]
18. Crawford J. Erythropoietin: high profile, high scrutiny [editorial]. J Clin Oncol 2007; 25 (9): 1021-2
19. Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004; 20 (3): 381-95
20. Papatheofanis FJ, McKenzie RS, Mody SH, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anaemia. Cur Med Res Opin 2006; 22 (5): 837-42
21. Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organizations. Drugs Aging 2006; 23 (12): 969-76
22. Duh MS, Mody SH, Scott McKenzie R, et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin Ther 2006; 28 (9): 1443-50
23. Shalansky K, Jastrzebski J. Complete switch to darbepoetin in a hemodialysis unit. Clin Nephrol 2005 Jul; 64 (1): 55-63
24. Brophy DF, Ripley EB, Kockler DR, et al. Darbepoetin alfa therapeutic interchange protocol for anaemia in dialysis. Ann Pharmacother 2005 Nov; 39 (11): 1808-11
25. Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health Syst Pharm 2005 Dec 15; 62: 2597-603
26. Ben-Hamadi R, Duh MS, Aggarwal J, et al. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anaemia. Curr Med Res Opin 2005; 21 (10): 1677-82
27. Rosberg JH, Ben-Hamadi R, Cremieux PY, et al. Dose conversion and cost-effectiveness of erythropoetic therapies in chemotherapy-related anaemia: a meta-analysis. Clin Drug Invest 2005; 25 (1): 33-48
28. Cremieux P, Vekeman F, Lefebvre P. Dose conversion and cost-effectiveness of erythropoetic therapies in chemotherapy-related anaemia: a Canadian application. J Oncol Pharm Practice 2006; 12: 165-78
29. Reed SD, Radeva JI, Daniel DB, et al. Economic evaluation of weekly epoetin alpha versus biweekly darbepoetin alpha for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. Pharmacoeconomics 2006; 24 (5): 479-94
30. Rosberg J, Koeller J, Oster E, et al. Clinical response, cost of treatment, and cost-effectiveness of three regimens of two erythropoietic agents for treating chemotherapy-induced anaemia [abstract no. 2250]. Proc Am Soc Clin Oncol 2003; 22: 2250
31. Barosi G, Marchetti M, Liberato ML. Cost effectiveness of recombinant human erythropoietin in the prevention of chemo_therapy-induced anemia. Br J Cancer 1998; 78: 781-7
32. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta, and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007; 11 (13): 1-220
33. Cersosimo RJ, Jacobson DR. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anaemia. Ann Pharmacother 2006 Jan; 40 (1): 58-65
34. Ben-Hamadi R, Duh MS, Henckler A, et al. Cost-effectiveness of once weekly epoetin alfa and darbepoetin alfa in treating chemotherapy-induced anaemia [abstract no. 6093]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (16s): 6093
35. Cremieux P, Greenberg P, Piech CT. Epoetin alfa is more effective and less costly relative to darbepoetin alfa in lung cancer patients receiving treatment for chemotherapy-induced anaemia [abstract no. 2248]. Proc Am Soc Clin Oncol 2003; 22: 2248
36. Duh MS, Mark TL. Cost-effectiveness of epoetin alpha and darbepoetin alpha in patients with chemotherapy-related anaemia. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5 (4): 383-94
37. Mark TL, McKenzie RS, Fastenau J, et al. Retrospective observational study of patients with chemotherapy-related anaemia receiving erythropoietic agents. Curr Med Res Opin 2005; 21 (9): 1347-54
38. McKenzie RR, Mark T, Piech CT. Better early and overall hematologic outcomes and lower drug cost with epoetin alfa (EPO) compared to darbepoetin alfa (DARB) in colorectal patients [abstract no. 232]. Gastrointestinal Cancer Symposium, 2004 Jan 22-24, San Francisco (CA)
39. Persson U, Borg S, Jansson S, et al. Epoetin alpha and darbepoetin alpha for the treatment of chemotherapy-related anaemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response. Adv Ther 2005; 22 (3): 208-24
40. Spaepen E, Demarteau N, Bracco A, et al. Health economic evaluation of anaemia treatment in patients with non-myeloid malignancies: a Belgian hospital perspective [abstract no. 630P]. 31st European Society for Medical Oncology Congress, 2006 Sep 29-Oct 3, Istanbul
41. Coiffier B, Schlag R, Velasco A, et al. Cost and effectiveness of darbepoetin alfa administered every 3 weeks compared with weekly epoetin alfa or epoetin beta in patients with chemotherapy induced anaemia: a retrospective study [abstract no. 1016P]. 31st European Society for Medical Oncology Congress, 2006 Sep 29-Oct 3, Istanbul
42. Chen E, Peake C, Buscaino E, et al. Hematologic outcomes and erythropoiesis-stimulating therapy costs in epoetin alfa (EPO)-and Darbepoetin Alfa (DARB)-treated cancer patients: results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E. Registry) [abstract no. 3340]. Blood 2006 Nov 18; 108 (11): 3340
43. Lefebvre P, Gosselin A, McKenzie RS, et al. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 2006; 22 (9): 1623-31
44. Reichardt B. Cost comparison of epoetin alpha, epoetin beta, and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. J Clin Pharm Ther 2006; 31: 503-12
45. Killian AD, Gupta V, Goetz AE. Cost analysis of erythropoietic- stimulating therapy dosing in oncology inpatients. Ann Pharmacother 2006 Mar; 40 (3): 421-6
46. Duh MS, Lefebvre P, Fastenau J, et al. Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. Oncologist 2005; 10: 438-48
47. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005; 23 (12): 2606-17
48. Kotasek D, Canon J-L, San Miguel J, et al. Correction/maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized phase 3 active controlled trial [poster presentation]. American Society of Hematology; 2004 Dec 4-7; San Diego (CA)
49. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007 Mar 20; 25 (9): 1027-32
50. Danish Head and Neck Cancer Group. Interim analysis of DAHANCA 10. December 2006 [online]. Available from URL: http://www.dahanca.dk/ get_media_file.php?.mediaid=125 [Accessed 2007 Jun 11]
51. Amgen. Aranesp® phase 3 study in patients with active cancer not receiving concurrent chemotherapy or radiotherapy presented at AACR Annual Meeting [press release]. 2007 Apr 16 [online]. Available from URL: http://www.amgen.com/media/media_pr_detail.jsp?.year=2007&releaseID=985366 [Accessed 2007 Jun 11]
52. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anaemia occurring during hepatitis C combination therapy. Hepatology 2006; 44 (6): 1598-606
53. Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Aliment Pharmacol Ther 2006 Oct 1; 24 (7): 1067-77
54. Spiegel BM, Chen K, Chiou CF, et al. Erythropoietic growth factors for treatment-induced anaemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005 Oct; 3 (10): 1034-42
55. Lucas C, Carrera F, Jorge C, et al. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients. Nephrol Dial Transplant 2006; 21: 3202-6
56. Coyle D, Lee KM, Fergusson DA, et al. Cost-effectiveness of epoetin-α to augment preoperative autologous blood donation in elective surgery. Pharmacoeconomics 2000 Aug; 18 (2): 161-71
57. Marchetti M, Barosi G. Cost-effectiveness of epoetin and autologous blood donation in reducing allogeneic blood transfusions in coronary artery bypass graft surgery. Transfusion 2000 Jun; 40: 673-81
58. Nieder AM, Rosenblum N, Lepor H. Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. Urology 2001 Apr; 57 (4): 737-41
59. MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health 2005 Mar-Apr; 8 (2): 105-16
60. Shermock KM, Horn E, Lipsett PA, et al. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005; 33 (3): 497-503
61. Yeo CL, Choo S, Ho L. Effect of recombinant erythropoietin on transfusion needs in preterm infants. J Paediatric Child Health 2001; 37: 352-8
62. Pajoumand M, Erstad BL, Camamo JM. Use of epoetin alfa in critically ill patients. Ann Pharmacother 2004 Apr; 38 (4): 641-8
63. Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacogenomics 1992 May; 1 (5): 346-56
64. Reḿak E, Hutton J, Jones M, et al. Changes in cost-effectiveness over time: the case of epoetin alfa for renal replacement therapy patients in the UK. Eur J Health Econom 2003; 4: 115-21
65. Cornes P, Coiffier B, Zambrowski JJ. Erythropoietin therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option. Curr Med Res Opin 2007 Feb; 23 (2): 357-68
66. Cremieux P, Finkelstein S, Berndt E, et al. Cost-effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999; 16: 459-72
67. Ross SD, Allen E, Henry D, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anaemia: a systematic review of the literature. Clin Ther 2006; 28 (6): 801-31
68. Marchetti M, Barosi G. Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 2004; 22 (16): 1029-45
69. Food and Drug Administration. FDA Public Health Advisory. Erythropoiesis-stimulating agents [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/RHE2007.htm [Accessed 2007 May 1]
70. US Food and Drug Administration. Center for Drug Evaluation and Research. Department of Health and Human Services. Information on erythropoiesis stimulating agents [ESA] (marketed as Procrit, Epogen, and Aranesp) [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/RHE/ [Accessed 2007 Apr 30]
71. Tonelli M, Winkelmayer WC, Jindal KK, et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003 Jul; 64 (1): 295-304
72. Centers for Medicare and Medicaid Services. Decision memo for erythropoiesis stimulating agents (ESAs) for nonrenal disease indications (CAG-00383N) [online]. Available from URL: https://www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?.id=203 [Accessed 2007 Sep 3]
73. Twachtman G. Medicare ESA coverage will not experiment with clinical trial approach. The Pink Sheet 2007 Aug; 69 (032): 21
74. Singh AK, Szczech L, Tang K, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 Nov 16; 355: 2085-98
75. Campos SM, Duh MS, Lefebvre P, et al. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw 2005; 3: 807-16